p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

References

• Chipuk J E, Green D R. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13: 994–1002
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322–3329
   PubMed Web of Science ®Google Scholar
• el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Robin V, Francart J, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 2007; 21: 1715–1722
   PubMed Web of Science ®Google Scholar
• Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 439–453
   PubMed Web of Science ®Google Scholar
• Xu W, Li J Y, Wu Y J, et al. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008; 32: 1071–1077
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239
   PubMed Web of Science ®Google Scholar
• Grever M R, Lucas D M, Dewald G W, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799–804
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15: 995–1004
   PubMed Web of Science ®Google Scholar
• Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117–124
   PubMed Web of Science ®Google Scholar
• Best O G, Gardiner A C, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008; 22: 1456–1459
   PubMed Web of Science ®Google Scholar
• Vojtesek B, Bartek J, Midgley C A, Lane D P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237–244
   PubMed Web of Science ®Google Scholar
• Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 1994; 8: 1342–1349
   PubMed Web of Science ®Google Scholar
• Villuendas R, Piris M A, Algara P, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993; 82: 3151–3156
   PubMed Web of Science ®Google Scholar
• Cordone I, Masi S, Mauro F R, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91: 4342–4349
   PubMed Web of Science ®Google Scholar
• Giles F J, Bekele B N, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol 2003; 121: 578–585
   PubMed Web of Science ®Google Scholar
• Cheson B D, Leonard J P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613–626
   PubMed Web of Science ®Google Scholar
• Tam C S, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Glassman A B, Hayes K J. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2005; 158: 88–91
   PubMed Web of Science ®Google Scholar
• Keating M J, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088
   PubMed Web of Science ®Google Scholar
• Borthakur G, O'Brien S, Wierda W G, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors. Br J Haematol 2007; 136: 800–805
   PubMed Web of Science ®Google Scholar
• Admirand J H, Rassidakis G Z, Abruzzo L V, Valbuena J R, Jones D, Medeiros L J. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004; 17: 954–961
   PubMed Web of Science ®Google Scholar
• Raval A, Lucas D M, Matkovic J J, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3877–3885
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614
   PubMed Web of Science ®Google Scholar
• Lin K I, Tam C S, Keating M J, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2008; 113: 3168–3171
   PubMed Web of Science ®Google Scholar
• Erol N, Oner U, Artan S, Isiksoy S, Yurdakul S. Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma. Melanoma Res 2004; 14: 473–478
   PubMed Web of Science ®Google Scholar
• Heselmeyer K, Hellstrom A C, Blegen H, et al. Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int J Gynecol Pathol 1998; 17: 245–254
   PubMed Web of Science ®Google Scholar
• Eyfjord J E, Thorlacius S, Valgardsdottir R, Gretarsdottir S, Steinarsdottir M, Anamthawat-Jonsson K. TP53 abnormalities and genetic instability in breast cancer. Acta Oncol 1995; 34: 663–667
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Faderl S, et al (2007) Complex karyotypic abnormalities detected by conventional cytogenetic analysis more strongly predict survival than FISH, ZAP70, or IgVH mutation status for previously treated patients with CLL. American Society of Hematology Annual Meeting, Atlanta, GA: Blood, December, 2007, 615A
   Google Scholar
• Han T, Henderson E S, Emrich L J, Sandberg A A. Prognostic significance of karyotypic abnormalities in B cell chronic lymphocytic leukemia: an update. Semin Hematol 1987; 24: 257–263
   PubMed Web of Science ®Google Scholar
• Oscier D G, Fitchett M, Hamblin T J. Chromosomal abnormalities in B-CLL. Nouv Rev Fr Hematol 1988; 30: 397–398
   PubMedGoogle Scholar
• Crossen P E. Genes and chromosomes in chronic B-cell leukemia. Cancer Genet Cytogenet 1997; 94: 44–51
   PubMed Web of Science ®Google Scholar
• Dierlamm J, Michaux L, Criel A, et al. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997; 94: 27–35
   PubMed Web of Science ®Google Scholar
• Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998; 25: 19–26
   PubMed Web of Science ®Google Scholar
• O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code?. Drug Resist Update 2003; 6: 313–322
   PubMed Web of Science ®Google Scholar
• Fu L, Minden M D, Benchimol S. Translational regulation of human p53 gene expression. EMBO J 1996; 15: 4392–4401
   PubMed Web of Science ®Google Scholar
• Tasdemir E, Chiara Maiuri M, Morselli E, et al. A dual role of p53 in the control of autophagy. Autophagy 2008; 4: 810–814
   PubMed Web of Science ®Google Scholar
• Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995; 147: 790–798
   PubMed Web of Science ®Google Scholar
• Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Invest 2002; 20: 509–517
   PubMed Web of Science ®Google Scholar